today announc acq celgen otezla net tax
benefit financ cash hand acq wont impact annual dividend increas stock
repurchas deal highli strateg synergist accret immedi
ep view net price attract peak sale deal
boost dcf
base feedback bristol-my squibb scala deal like competit
view price peak sale attract derisk
profit growth commerci asset asset hard come fact
financ deal cash highli attract asset
offer first class moa littl direct competit sever growth
indic ahead henc uniqu opportun highli strateg
continu transform enbrel solid foot see prior two note
topic
sale oper margin boost ep
see otezla cumul sale averag
oper margin translat pre-tax profit base math
boost dcf assum product lose global exclus
deal also boost compound-annual-growth-rate total rev non-gaap ep
bp see deal boost non-gaap ep
deal highli accret amgen slightli increas opex due strength
busi posit sign
base strength busi assum deal close ye guid
non-gaap increas y/i due otezla
amount non-gaap sg note welcom fte
celgen global level sg increas assum continu
spend product sale sg view increas opex guidanc
due strength busi due accret deal
base project otezla sale assum sg
 spend oper profit see increas
peak steadi basi due synergi global growth otezla
sale assum otezla sale growth
pleas see page report import disclosur
like fundament due diversifi product mix biolog franchis
durabl protect product innov pipelin tight control opex
aggress cash return sharehold see near-term risk enbrel sensipar
gener challeng new product launch includ aimovig biosimilar
provid new growth prospect legaci franchis declin opinion amgen
continu provid sustain growth navig turbul water
legaci franchis erod meantim tezepelumab earli stage oncolog pipelin
gain visibl shore confid long-term prospect
updat data phase studi kra
updat sensipar gener litig
potenti data bite platform
grow dividend consist stock
neulasta enbrel sensipar eros
less expect
aimovig biosimilar tezepelumab
tezepelumab success becom
revenu growth greater
pipelin contribut substanti
valu model
biosimilar launch exceed
neulasta rapid share loss sensipar
tezepelumab drug
aimovig slow
fail rais dividend pursu
success navig biosimilar competit legaci franchis
still contend patent challeng age brand nevertheless tight opex
control margin expans stock buyback new product launch ep growth
resili manag grow dividend annual major brand includ enbrel
sale neulasta denosumab franchis brand xgeva cancer
prolia osteoporosi sale aranesp/epogen like
tezepelumab asthma earli stage oncolog pipelin solid liquid tumor
biosimilar franchis aimovig also provid attract growth venu
view celgen celg market perform otezla attract commerci
asset acquir therapeut fit enbrel differ moa
stand ftc scrutini potenti high profit use enbrel sale forc
otezla growth asset potenti label expans mod/sever scalp mild/
moder psoriasi drug approv countri launch
like launch new territori
drug highli synergist strateg would bolster presenc europ
japan like acquir joint ventur japan astella
bolster infrastructur amjevita biosimilar humira global basi
deal reduc tax rate project npv tax benefit
word actual cash benefit reduc tax rate due
deal henc view net effect price deal note
tax benefit amort intang next year
accru basi non- guid non- tax rate ie
non-cash basi increas approxim
morn mdco report posit top-lin result first three
pivot trial expect report announc
follow expect studi met primari secondari endpoint primari
endpoint percent chang ldl-c baselin day time-adjust percent
chang ldl-c baselin day day secondari endpoint
includ absolut ldl-c chang baselin day time-adjust absolut ldl-c
chang baselin day day percent chang total
cholesterol apob non-hdl-c baselin day
full data releas european societi cardiolog esc mdco hold
confer call monday sept et
view inclisiran viabl threat repatha given dose reduct
prior studi drug antisens target highli valid
target repatha also target safeti key element watch
view global sale estim repatha risk due
requir strong market growth achiev estim competit
headwind inclisiran
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
forecast sale product difficult outlook could alter
competit clinic develop failur reimburs chang new competit
could also impact sale estim pipelin product might fail develop
risk includ clinic develop regulatori price commerci challeng may
prevent financi forecast materi
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock celgen ultragenyx secur
cowen compani llc manag co-manag public offer ultragenyx past month
cowen compani llc receiv compens invest bank servic ultragenyx past month
cowen compani llc and/or affili expect receiv intend seek compens invest bank servic next month ultragenyx
ultragenyx past month client cowen compani llc cowen compani llc provid provid invest bank servic
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
